Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser zaps nose nerves to stop sniffles in new trial

NCT ID NCT07050992

Symptom relief Sponsor: Chiayi Christian Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a laser procedure that targets nerves in the nose to relieve chronic rhinitis symptoms like runny nose, sneezing, and stuffiness. 120 adults who haven't gotten relief from standard medications will receive either the laser treatment or a sham procedure. Researchers will track symptom scores and side effects for three months after the single in-office treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
laser posterior nasal nerve neurolysis (a procedure using laser energy to ablate nerves in the nose)
What this could lead to
If it works, this could offer a long-lasting, in-office procedure to reduce chronic rhinitis symptoms like runny nose and congestion without daily medication.
What could go wrong
This is a small, early-stage trial with no phase designation. The sham surgery control may reveal a strong placebo effect, and the procedure carries risks like bleeding or scarring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years old * Chronic rhinitis symptoms for at least 6 months that have not responded effectively to medication (should include at least Intranasal corticosteroid (ICS) combined with intermittent use of oral antihistamine and, as needed, combination nasal spray) or where medication has not provided sustained improvement * Total rTNSS ≥ 5 with Moderate to severe rhinorrhea symptoms (24-hour reflective Total Nasal Symptom Score \[rTNSS\] rhinorrhea score of 2-3) and mild to severe nasal congestion symptoms (rTNSS nasal congestion score of 1-3) * All enrolled patients routinely undergo endonasal endoscopic examination, or have had a sinus CT within the past month confirming no significant rhinosinusitis." Exclusion Criteria: * Obstructive anatomical abnormalities limiting access to posterior nasal passages * Nasal anatomical changes due to previous sinus or nasal surgery or injury * Ongoing nasal or sinus infection * History of severe dry eye, chronic epistaxis, rhinitis medicamentosa, or head and neck radiotherapy * Self-reported history of bleeding tendency * Current use of anticoagulants with inability to discontinue * Previous chronic rhinitis surgery * History of poor wound healing after head, neck, or throat surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease allergic rhinitis chronic rhinitis Nasal Obstruction rhinitis Rhinitis, Allergic Rhinorrhea Sneezing

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis Chronic rhinitis Nasal allergies Nasal congestion Nasal obstruction Nasal stuffiness Rhinorrhea Sneezing

Contacts and locations

Locations

  • Ditmanson Medical Foundation Chia-Yi Christian Hospital

    Chiayi City, Taiwan, 600, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.